A Retrospective Analysis of a Cohort of Patients Treated With Immune Checkpoint Blockade in Recurrent/Metastatic Head and Neck Cancer
Michel Bila(Universitair Ziekenhuis Leuven), Paul M. Clément(Universitair Ziekenhuis Leuven), Jeroen Van Dessel(Universitair Ziekenhuis Leuven), Jeroen Meulemans(KU Leuven), Vincent Vander Poorten(KU Leuven), Sandra Nuyts(Cancer Institute (WIA)), Maximiliaan Smeets(Amphia Ziekenhuis)
Cited by 7
Related Papers
Lomustine and Bevacizumab in Progressive Glioblastoma
|New England Journal of Medicine|2017|994
Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034
|Journal of Clinical Oncology|2009|573
Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study
|The Lancet Oncology|2016|504